Michael Ehlers becomes company’s new executive vice president of research and development.
He will oversee the company’s global research, drug discovery, clinical development and medical affairs functions, Biogen said. In his role, he will lead efforts to develop therapies for patients with few or no treatment options. Ehlers is expected to begin his tenure at the company in May.
Mr. Ehlers appointment replaces a vacancy created by Doug Williams who left Biogen to launch his own company, Codiak Biosciences, Inc., a company focused on developing exosome-based therapies and products.